Citations

Clear

3042 citation(s) found for "Kumar, S".

Incidence, Admission Rates, and Predictors, and Economic Burden of Adult Emergency Visits for Acute Pancreatitis
Garg, Sushil Kumar , Sarvepalli, Shashank , Campbell, James P. , Obaitan, Itegbemie , Singh, Dupinder, Singh, Rajeshwar, Sanaka, Madhusudhan R. , Garg, Sushil K, Bazerbachi, Fateh

Mayo Clinic

Journal of Clinical Gastroenterology | April 8, 2018 | Volume: 53 | Issue: 3 | Pages: 220-225

10.1097/mcg.0000000000001030 | PMID 29629907 Get It

Introduction: Acute pancreatitis (AP) is the most common gastroenterology-related reason for hospital admission, and a major source of morbidity and mortality in the United States. This study examines the National Emergency Database Sample, a large national database, to analyze trends in emergency department (ED) utilization and costs, risk factors for hospital admission, and associated hospital costs and length of stay (LOS) in patients presenting with AP. Methods: The National Emergency Database Sample (2006 to 2012) was evaluated for trends in ED visits, ED charges, hospitalization rates, hospital charges, and hospital LOS in patients with primary diagnosis of AP (further subcategorized by age and etiology). A survey logistic-regression model was used to determine factors predictive of hospitalization. Results: A total of 2,193,830 ED visits were analyzed. There was a nonsignificant 5.5% ( P =0.07) increase in incidence of ED visits for AP per 10,000 US adults from 2006 to 2012, largely driven by significant increases in ED visits for AP in the 18 to <45 age group (+9.2%; P =0.025), AP associated with alcohol (+15.9%; P =0.001), and AP associated with chronic pancreatitis (+59.5%; P =0.002). Visits for patients aged ≥65 decreased over the time period. Rates of admission and LOS decreased during the time period, while ED and inpatient costs increased (62.1%; P <0.001 and 7.9%; P =0.0011, respectively). Multiple factors were associated with increased risk of hospital admission from the ED, with the strongest predictors being morbid alcohol use [odds ratio (OR), 4.53; P <0.0001], advanced age (age>84 OR, 3.52; P <0.0001), and smoking (OR, 1.75; P <0.0001). Conclusions: Despite a relative stabilization in the overall incidence of ED visits for AP, continued increases in ED visits and associated costs appear to be driven by younger patients with alcohol-associated and acute on chronic pancreatitis. While rates of hospitalization and LOS are decreasing, associated inflation-adjusted costs are rising. In addition, identified risk factors for hospitalization, such as obesity, alcohol use, and increased age, should be explored in further study for potential use in predictive models and clinical improvement projects.
Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation
Sidiqi, M Hasib , Aljama, Mohammed A. , Muchtar, Eli , Warsame, Rahma , Lacy, Martha Q. , Dingli, David , Kumar, Shaji , Kapoor, Prashant , Kourelis, Taxiarchis , Buadi, Francis K. , Kourelis, Taxiarchis V, Gertz, Morie A , Muchtar, E , Sidiqi, M Hasib , Dingli, David , Dispenzieri, Angela , Leung, Nelson , Gonsalves, Wilson I. , Hogan, William J. , Gertz, Morie A.

Mayo Clinic

Blood Advances | April 3, 2018 | Volume: 2 | Issue: 7 | Pages: 769-776

10.1182/bloodadvances.2018016782 | PMID 29615413 Get It

Key Points λ Light chain AL amyloidosis is associated with a shorter PFS and OS compared with κ. Light chain type predicts likelihood of organ involvement in AL amyloidosis.
Metastatic Spinal Cord Compression and Steroid Treatment
Kumar, Abhishek , Weber, Michael H. , Gokaslan, Ziya L. , Wolinsky, Jean‐Paul , Schmidt, Meic H. , Rhines, Laurence D. , Fehlings, Michael G. , Laufer, Ilya , Sciubba, Daniel M. , Sundaresan, Narayan, Verlaan, Jorrit‐Jan , Sahgal, Arjun , Chou, Dean , Fisher, Charles G. , Fehlings, Michael G , Clarke, Michelle J.

Mayo Clinic

Clinical Spine Surgery: A Spine Publication | March 30, 2018 | Volume: 30 | Issue: 4 | Pages: 156-163

10.1097/bsd.0000000000000528 | PMID 28437329 Get It

Study Design: Systematic review. Objectives: We conducted a systematic review of the literature to answer the following questions regarding the use of steroid therapy in metastatic spinal cord compression (MSCC): 1. In cases of MSCC, what is the effect of steroid administration before definitive radiotherapy or surgery on ambulatory status, bowel and bladder function and survival? 2. What steroid dosing regimens are associated with the best outcomes concerning neurological symptoms and complication prevention in cases of MSCC? Summary of Background Data: Currently, there is significant variation in the initial bolus dose, daily maintenance dose and duration of treatment when steroids are used as a bridge to definitive therapy for MSCC. Methods: A literature search following PRISMA guidelines was conducted in June 2016, using Medline via Ovid SP, Medline via PubMed, Embase, Biosis Previews and the Cochrane Library. Search terms used in each database varied slightly to optimize results. All generic steroid formulations were included along with spinal cord compression or myelopathy combined with metastatic or malignant tumors. Papers discussing acute traumatic causes of spinal cord compression were excluded, as were papers discussing cord compression from nonmetastatic tumors or epidural lipomatosis. Subjects were limited to adult humans undergoing definitive treatment with radiotherapy or surgery. Results: Of the 309 papers retrieved, 66 full text studies were reviewed and 6 papers were found to address the stated questions. Conclusions: There is a paucity of high quality literature evaluating the use of steroids in MSCC. On the basis of the evidence available an initial 10 mg intravenous bolus of dexamethasone followed by 16 mg PO QD has been associated with fewer complications compared with 100 mg bolus and 96 mg QD. Weaning of steroids should occur rapidly after definitive treatment. Risk of gastric bleeding or perforation can be managed with the routine use of proton-pump inhibitors. Level of Evidence: Level IIIa.
Vitamin D Status and Cardiovascular Risk in Obesity: Effect of Physical Activity in Nonvitamin D Supplemented Adolescents
Hossain, Jobayer , Levinson, Alexa, George, Donald E. , Canas, Jose A. , Kumar, Seema , Balagopal, Prabhakaran

Mayo Clinic

Metabolic Syndrome and Related Disorders | March 29, 2018 | Volume: 16 | Issue: 4 | Pages: 197-203

10.1089/met.2017.0171 | PMID 29649377 Get It

Inpatient burden of esophageal cancer and analysis of factors affecting in-hospital mortality and length of stay
Sarvepalli, Shashank , Garg, Sushil Kumar , Parikh, Malav P., Jang, Sunguk , Thota, Prashanthi N. , Sanaka, Madhusudhan R. , Wadhwa, Vaibhav

Mayo Clinic

Diseases of the Esophagus | March 29, 2018 | Volume: 31 | Issue: 9 | Pages: No page available

10.1093/dote/doy022 | PMID 29617798 Get It

Summary Esophageal cancer (EC) continues to be a major source of morbidity and mortality in the United States. However, there has been a relative dearth of research into hospital utilization in patients with EC. This study examines temporal trends in hospital admissions, length of stay (LOS), mortality, and costs associated with EC. In addition, we also analyzed factors associated with inpatient mortality and LOS. We interrogated National Inpatient Sample (NIS), a large registry of inpatient data, to retrieve information about various demographic and factors associated with hospital stay in patients who were admitted for EC between the years 1998 and 2013 in the United States. After examining trends over time, multivariate analysis was performed to identify factors associated with LOS and mortality. During 1998–2013, 538,776 hospital stays with principal diagnosis of EC were reviewed. Number of hospital stays and inpatient charges increased by 397 per year (±67.8;P &lt; 0.0001) and $3,033 per patient per year (±135; &lt;0.0001) respectively. Mortality and LOS decreased by 0.23% per year (±0.03;P &lt; 0.0001) and 0.07 days per year (±0.006;P &lt; 0.0001) respectively. Multiple factors associated with LOS and mortality were outlined. Despite overall increase in hospital utilization with respect to number of admissions and inpatient charges, inpatient mortality and LOS associated with EC declined. Factors associated with inpatient mortality and LOS may help drive clinical decision-making and influence healthcare or hospital policy.
A rapid and reliable chromosome analysis method for products of conception using interphase nuclei
Babu, Ramesh , Dyke, Daniel L. Van , Bhattacharya, Saurabh Kumar , Dev, Vaithilingam G., Liu, Mingya, Kwon, Minjae, Gu, Guangyu , Koduru, Prasad , Rao, Nagesh, Williamson, Cynthia M., Fuentes, Sarah, Papa, Stephen, Kopuri, Srikanthi, Lal, Vandana , Van Dyke, Daniel L, Williamson, Cynthia, Fuentes, Ernesto J.

Mayo Clinic

Molecular Genetics & Genomic Medicine | March 24, 2018 | Volume: 6 | Issue: 3 | Pages: 370-381

10.1002/mgg3.381 | PMID 29573570 Get It

AbstractBackgroundKaryotype determination has a central role in the genetic workup of pregnancy loss, as aneuploidy (trisomy and monosomy) and polyploidy (triploidy and tetraploidy) are the cause in at least 50% of first trimester, 25% of second trimester, and 11% of third trimester miscarriages. There are several limitations with the current approaches of obtaining a karyotype using traditional cytogenetics, fluorescence in situ hybridization with a limited number of probes, and chromosomal microarray. These include culture failure, incomplete results, lower sensitivity, and longer reporting time.MethodsTo overcome current limitations, a novel molecular assay is developed with a Standard Resolution Interphase Chromosome Profiling probe set which is a variation of the recently developed High Resolution probe set. It generates a molecular karyotype that can detect all major changes commonly associated with pregnancy loss. Initial familiarization of signal patterns from the probe set was used, followed by validation of the method using 83 samples from miscarriages in a blind study from three different laboratories. Finally, the clinical utility of the method was tested on 291 clinical samples in two commercial reference laboratory settings on two different continents.ResultsThe new molecular approach not only identified all the chromosome changes observed by current methods, but also significantly improved abnormality detection by characterizing derivative chromosomes and finding subtle subtelomeric rearrangements, balanced and unbalanced. All Robertsonian translocations were also detected. The abnormality rate was 54% on clinical samples from commercial laboratory 1 and 63% from laboratory 2.ConclusionThe attributes of this method make it an ideal choice for the genetic workup of miscarriages, namely (1) near 100% successful results, (2) greater sensitivity than conventional chromosome analysis or FISH panels, (3) rapid reporting time, and (4) favorable comparisons with chromosomal microarray.
Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time
Sidiqi, M Hasib , Aljama, Mohammed A. , Warsame, Rahma , Lacy, Martha Q. , Dingli, David , Kumar, Shaji , Kapoor, Prashant , Kourelis, Taxiarchis , Buadi, Francis K. , Warsame, Rahma M, Sidiqi, M Hasib , Dingli, David , Dispenzieri, Angela , Gonsalves, Wilson I. , Hogan, William J. , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | March 20, 2018 | Volume: 36 | Issue: 13 | Pages: 1323-1329

10.1200/jco.2017.76.9554 | PMID 29558277 Get It

Purpose Autologous stem-cell transplantation (ASCT) has been used in patients with immunoglobulin light chain (AL) amyloidosis for more than two decades. Early experience raised concerns regarding safety with high early-mortality rates. Patients and Methods We report 20 years of experience with ASCT for AL amyloidosis at the Mayo Clinic Rochester. In all, 672 consecutive patients receiving ASCT for AL amyloidosis were divided into three cohorts on the basis of date of transplantation (cohort 1, 1996-2002 [n = 124]; cohort 2, 2003-2009 [n = 302]; and cohort 3, 2010-2016 [n = 246]). Results The median age for the entire cohort was 59 years, with patients in cohort 3 being slightly older than those in the other two cohorts (60 v 58 v 54 years for cohorts 3, 2, and 1, respectively; P < .001). Fewer patients in cohort 3 had more than two organs involved (9% v 18% v 19% for cohorts 3, 2, and 1, respectively; P < .001). More patients received pretransplantation therapy in cohort 3 compared with earlier time periods (49% v 38% v 42% for cohorts 3, 2, and 1, respectively; P = .02). Hematologic response was higher in cohort 3 (84% v 79% v 69% for cohorts 3, 2, and 1, respectively; P = .002). Median overall survival for the entire cohort was 122 months and improved over time (not reached v 120 months v 75 months for cohorts 3, 2, and 1, respectively; P < .001). Treatment-related mortality declined over time (2.4% v 8.6% v 14.5% for cohorts 3, 2, and 1, respectively; P < .001). On multivariable analysis, conditioning dose, Mayo stage 2012, and hematologic response were independent predictors of survival. Conclusion ASCT is a highly effective therapy for AL amyloidosis. The improved survival and markedly reduced treatment-related mortality in eligible patients indicate that this will remain an important first-line option even in the era of treatment approaches that use novel agents.
Cardiometabolic risk factors in treatment‐seeking youth versus population youth with obesity
Fox, Claudia K. , Kaizer, Alexander , Ryder, Justin R. , Rudser, Kyle , Kelly, Aaron S. , Kumar, Seema , Gross, Amy C. , Group, on behalf of POWER Work, Fox, C K , Ryder, J R , Group, on behalf of POWER Work, Kaizer, Alexander M , Kelly, Aaron S

Mayo Clinic

Obesity Science & Practice | March 15, 2018 | Volume: 4 | Issue: 3 | Pages: 207-215

10.1002/osp4.166 | PMID 29951211 Get It

SummaryBackgroundAlthough obesity affects approximately one in five youths, only a fraction is treated in pediatric weight management clinics. Characteristics distinguishing youth with obesity who seek weight management treatment from those who do not are largely unknown. Yet identification of specific health characteristics which differentiate treatment‐seeking from non‐treatment seeking youth with obesity may shed light on underlying motivations for pursuing treatment.ObjectivesCompare the cardiometabolic profiles of an obesity treatment‐seeking sample of youth to a population‐based sample of youth with obesity, while controlling for body mass index (BMI).MethodsThis cross‐sectional study included participants, ages 12–17 years, with obesity from the Pediatric Obesity and Weight Evaluation Registry (POWER) and National Health and Nutrition Examination Survey, representing the treatment‐seeking and population samples, respectively. Mean differences were calculated for systolic and diastolic blood pressure percentiles, total cholesterol, low‐density and high‐density lipoprotein‐cholesterol, triglycerides, fasting glucose, glycated hemoglobin and alanine aminotransferase, while adjusting for age, sex, race/ethnicity, insurance status, and multiple of the 95th BMI percentile.ResultsThe POWER and National Health and Nutrition Examination Survey cohorts included 1,823 and 617 participants, respectively. The POWER cohort had higher systolic blood pressure percentile (mean difference 17.4, 95% confidence interval [14.6, 20.1], p < 0.001), diastolic blood pressure percentile (21.8 [19, 24.5], p < 0.001), triglycerides (42.3 [28, 56.5], p < 0.001) and alanine aminotransferase (7.5 [5.1, 9.8], p < 0.001) and lower fasting glucose (−6.9 [−8.2, −5.6], p < 0.001) and high‐density lipoprotein‐cholesterol (−2.3 [−3.8, −0.9], p < 0.002). There were no differences in total cholesterol or low‐density lipoprotein‐cholesterol or clinical differences in glycated hemoglobin.ConclusionFor a given BMI, obesity treatment‐seeking youth are more adversely affected by cardiometabolic risk factors than the general population of youth with obesity. This suggests that treatment‐seeking youth may represent a distinct group that is at particularly high risk for the development of future cardiometabolic disease.
Hospital Utilization in Patients With Gastric Cancer and Factors Affecting In-Hospital Mortality, Length of Stay, and Costs
Sarvepalli, Shashank , Garg, Sushil Kumar , Sarvepalli, Siri S. , Anugwom, Chimaobi M. , Thota, Prashanthi N. , Sanaka, Madhusudhan R. , Garg, Sushil K, Wadhwa, Vaibhav

Mayo Clinic

Journal of Clinical Gastroenterology | March 6, 2018 | Volume: 53 | Issue: 4 | Pages: e157-e163

10.1097/mcg.0000000000001016 | PMID 29517707 Get It

Introduction: Although gastric cancer (GC) rates have been declining in the United States, it continues to be a major cause of morbidity. This study examined trends in hospital admissions, in-hospital mortality, length of stay (LOS), and inpatient costs related to GC. In addition, various factors associated with in-hospital mortality, LOS, and inpatient costs were examined. Methods: National inpatient sample—the largest publicly available all-payer inpatient care database—was interrogated to obtain information about various demographic and hospital-related factors (including those mentioned above) in patients who were primarily admitted for GC between the years 1998 to 2013. These trends were analyzed. Multivariate analysis was also performed to identify risk factors associated with LOS, costs, and mortality. Results: A total of 679,330 hospital discharges with the principal diagnosis of GC were obtained. Hospital stays increased by approximately 340 stays per year (±110; P=0.00079). However, inpatient mortality rate and LOS declined by 0.36% per year (±0.024%; P<0.0001), and 0.11 days per year (±0.01; P<0.0001), respectively. The inpatient charges have increased at the rate of $3241 per year (±133.3; P<0.0001). Differences in mortality rate, LOS, and inpatient costs were affected by multiple factors. Conclusions: Despite the overall decline in GC incidence, the incidence of hospitalizations per 100,000 US population related to GC did not change significantly. Although LOS and mortality declined, inpatient charges increased over the study period.